IDEXX Laboratories (NASDAQ:IDXX) saw its stock soar 5.64% in pre-market trading on Monday following the release of its impressive third-quarter results and upgraded full-year guidance. The veterinary diagnostics company reported earnings that surpassed analyst expectations and raised its outlook for 2025, demonstrating strong growth across its business segments.

For the third quarter, IDEXX reported earnings per share of $3.40, up from $2.80 a year earlier and significantly beating the FactSet analyst consensus estimate of $3.14. Revenue for the quarter reached $1.11 billion, a 13.27% increase from $975.5 million in the same period last year, and comfortably exceeding the analyst expectations of $1.07 billion. The company's performance was driven by robust growth in its Companion Animal Group (CAG) diagnostics recurring revenue, which increased by 11% as reported.

In light of its strong performance, IDEXX raised its full-year 2025 guidance. The company now expects earnings per share between $12.81 and $13.01, up from its previous forecast of $12.40 to $12.76. Additionally, IDEXX increased its revenue guidance for the year to a range of $4.27 billion to $4.30 billion, up from $4.21 billion to $4.28 billion previously. This upward revision in guidance, coupled with the better-than-expected Q3 results, has fueled investor optimism and contributed to the significant pre-market stock price increase.